NCT02428270View on ClinicalTrials.gov

A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

October 27, 2022

Conditions
Pancreatic CancerAdenocarcinoma
Interventions
DRUG

GSK2256098

Small molecule inhibitor of focal adhesion kinase (FAK)

DRUG

Trametinib

Allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK)1 and MEK2 activation and kinase activity.

Trial Locations (4)

L8V 5C2

Juravinski Cancer Center, Hamilton

Unknown

London Regional Cancer Centre, London

The Ottawa Hospital Cancer Centre, Ottawa

M5G 2M9

Princess Margaret Cancer Centre, Toronto

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University Health Network, Toronto

OTHER